In this Issue:
Postoperative radiotherapy may improve NSCLC survival
Significant intratumoral heterogeneity in lung adenocarcinoma
Adjuvant erlotinib in EGFR-positive NSCLC: no DFS benefit
Nedaplatin + docetaxel for advanced squamous NSCLC?
A predominant histological pattern affects recurrence
Nivolumab vs docetaxel in advanced nonsquamous NSCLC
Belagenpumatucel-L looks promising in NSCLC
Survival after sublobar resection vs lobectomy in early-stage NSCLC
Limited resection vs lobectomy in older patients
Tivantinib + erlotinib: no OS advantage in nonsquamous NSCLC
Please login below to download this issue (PDF)